Company intelligence / Profile preview

Tecellact

Tsu, Mie, Japan

Ownership: Private
Development stage: Other

Overview

Tecellact is a Japanese biotechnology company focused on the development of next-generation T-cell receptor (TCR) engineered T-cell therapies for the treatment of solid tumors. The company leverages a proprietary platform to identify and optimize high-affinity TCRs targeting cancer-specific antigens such as NY-ESO-1 and MAGE-A4. By engineering a patient's own immune cells to recognize and attack malignant cells, Tecellact aims to provide effective treatment options for difficult-to-treat cancers like synovial sarcoma. The company is currently advancing its pipeline through pre-clinical validation with the goal of entering clinical trials.

Therapeutic areas: Oncology
Modalities: Cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Tecellact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tecellact.

Explore the full profile